Orkambi 100/125 (Lumacaftor + Ivacaftor Tablet) 100mg/125mg

ORKAMBI 100/125 (Lumacaftor + Ivacaftor) is a cystic fibrosis transmembrane conductance regulator modulator used to treat cystic fibrosis in patients with specific mutations. This tablet form combines two active ingredients to support lung function. Suitable for ambient storage, it comes in a 112-tablet pack.

Strength

100mg/125mg

Pack Size

112s

Storage

Ambient

Manufacturer / TM Owner

Almac Pharma Services Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ORKAMBI 100/125 is prescribed to improve lung function and reduce respiratory symptoms in people with cystic fibrosis who have two copies of the F508del mutation in the CFTR gene. It is used for long-term management of this condition. The combination of lumacaftor and ivacaftor helps correct the underlying protein defect. It is not a cure but may slow disease progression.

Side Effects

Users may notice improved breathing and fewer lung-related symptoms over time while taking ORKAMBI 100/125. Some people report better energy levels and reduced coughing or congestion. These effects vary by individual and may take several weeks to become noticeable. Regular use as directed is important for best results.

Precautions & Warnings

ORKAMBI 100/125 should be stored at room temperature away from moisture and heat. Keep out of reach of children and pets. Do not use if the packaging is damaged or the tablets appear discolored. Inform your healthcare provider about all medications and supplements you are taking before starting this treatment.

Avoid Interactions

Certain medications can affect how ORKAMBI 100/125 works, including strong CYP3A inducers like rifampin or St. John’s wort. Moderate CYP3A inhibitors may increase ivacaftor levels, requiring dose adjustments. Avoid grapefruit products while taking this medication. Always consult a healthcare professional before combining with other drugs.

Frequently Asked Questions

It is used to treat cystic fibrosis in patients with two copies of the F508del mutation in the CFTR gene.

Store at room temperature, away from moisture and heat, in the original packaging.

Yes, it is recommended to take this medication with food or a snack to improve absorption.

Common effects may include headache, nausea, or upper respiratory tract infections.

No, it is not a cure but may help manage symptoms and slow disease progression.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 28 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.